Dyne Therapeutics (DYN) Return on Capital Employed (2020 - 2026)
Dyne Therapeutics' (DYN) quarterly Return on Capital Employed came in at 43.53% in Q1 2026, up 1552.0% year-on-year from 2.64% in Q1 2025, and up 9.22% on a QoQ basis from 47.95% in Q4 2025.
Dyne Therapeutics (DYN) Return on Capital Employed (2020 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has 7 years of Return on Capital Employed data on file, last reported at 43.53% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 1552.0% year-over-year to 43.53% in Q1 2026; TTM through Mar 2026 was 43.53%, a 1552.0% increase from a year earlier, with the FY2025 full-year figure at 52.7%, up 3642.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 43.53%, up from 47.95% in the prior quarter.
- Over the last five years, Return on Capital Employed for DYN reached as high as 41.69% in Q3 2024 and fell as low as 180.63% in Q4 2023.
- Historically, Return on Capital Employed has averaged 67.31% across 5 years, with a median of 60.85% in 2025.
- Across the five-year window, Return on Capital Employed tumbled 11844 bps in 2023 and soared 13064 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 62.19% in 2022, then plunged by 190 bps to 180.63% in 2023, then soared by 72 bps to 49.99% in 2024, then grew by 4 bps to 47.95% in 2025, then gained by 9 bps to 43.53% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 43.53% in Q1 2026, 47.95% in Q4 2025, and 60.85% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Dyne Therapeutics | 3.94 Bn | 3.94 Bn | - | -43.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.53% |
| Dec 31, 2025 | -47.95% |
| Sep 30, 2025 | -60.85% |
| Jun 30, 2025 | -64.49% |
| Mar 31, 2025 | -59.06% |
| Dec 31, 2024 | -49.99% |
| Sep 30, 2024 | -41.69% |
| Jun 30, 2024 | -42.07% |
| Mar 31, 2024 | -82.74% |
| Dec 31, 2023 | -180.63% |
| Sep 30, 2023 | -108.04% |
| Jun 30, 2023 | -77.91% |
| Mar 31, 2023 | -65.47% |
| Dec 31, 2022 | -62.19% |
| Sep 30, 2022 | -61.64% |
| Jun 30, 2022 | -54.18% |
| Mar 31, 2022 | -41.90% |
| Dec 31, 2021 | -35.93% |
| Sep 30, 2021 | -28.55% |
| Dec 31, 2020 | -16.45% |